APA Annual Meeting

NEW YORK CITY—The investigational olanzapine-samidorphan drug ALKS 3831 did not outperform olanzapine alone in reducing alcohol use in patients with schizophrenia and alcohol use disorder, but it did improve symptoms of schizophrenia, a study found.


NEW YORK CITY—Public acceptance of the LGBTQ+ community has increased dramatically, but its members are still at increased risk for mental health challenges, panel members said at the American Psychiatric Association Annual Meeting here.


NEW YORK CITY—Using pharmacogenomic testing to guide medication selection for patients with depression improved rates of response and remission, researchers reported at the American Psychiatric Association’s annual meeting.

NEW YORK CITY—Patients who stop taking cariprazine for schizophrenia appear to have a longer period before relapse, compared with other oral atypical antipsychotics, according to research presented at the American Psychiatric Association’s annual meeting.

NEW YORK CITY—Five atypical antipsychotics are significantly more effective than placebo in easing symptoms of acute bipolar depression, a meta-analysis of 22 trials found.

NEW YORK CITY—A single treatment of botulinum toxin injections vastly improved treatment-resistant symptoms of borderline personality disorder in at least 10 consecutive cases, according to new research.